8-K: Capricor Therapeutics Reports Positive Progress on DMD Treatment and First Quarter 2025 Financial Results

Capricor Therapeutics announces progress on its Duchenne muscular dystrophy (DMD) treatment, deramiocel, and reports its first quarter 2025 financial results, highlighting a strong cash position.

Summary

• Capricor Therapeutics reported its first quarter 2025 financial results and provided a corporate update.
• The Biologics License Application (BLA) for deramiocel in the treatment of Duchenne muscular dystrophy (DMD) remains under priority review by the U.S. FDA, with a target Prescription Drug User Fee Act (PDUFA) date slated for August 31, 2025.
• A mid-cycle review meeting with the FDA was recently completed with no significant deficiencies identified, and a late cycle meeting is scheduled for June.
• The FDA has indicated its intent to convene an advisory committee meeting.
• Dr. Michael Binks has been appointed as Chief Medical Officer.
• The National Institute of Allergy and Infectious Diseases (NIAID) plans to initiate a phase 1 clinical trial of Capricor's StealthX exosome vaccine in the third quarter of 2025, subject to NIAID's regulatory approval.
• The company's cash balance of approximately $145 million is expected to support planned operations into 2027.
• Revenues for the first quarter of 2025 were $0 compared to $4.9 million for the first quarter of 2024.
• The Company reported a net loss of approximately $24.4 million, or $0.53 per share, for the first quarter of 2025, compared to a net loss of $9.8 million, or $0.31 per share, for the first quarter of 2024.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook, highlighting progress with the FDA review of deramiocel and a strong cash position. However, the increased net loss and lack of revenue in the first quarter temper the overall sentiment.

Positives

• The FDA granted priority review to Capricor's BLA for deramiocel, indicating a potentially faster path to approval.
• The mid-cycle review meeting with the FDA identified no significant deficiencies.
• The company has a strong cash position of approximately $145 million, expected to last into 2027.
• NIAID is advancing Capricor's StealthX vaccine platform with a planned Phase 1 clinical study.
• The company expanded its manufacturing capacity to support increased commercial production.

Negatives

• Revenues for the first quarter of 2025 were $0, a decrease from $4.9 million in the first quarter of 2024.
• The company reported a net loss of approximately $24.4 million for the first quarter of 2025, compared to a net loss of $9.8 million for the first quarter of 2024.
• The FDA intends to convene an advisory committee meeting, which could introduce uncertainty into the approval process.

Risks

• The FDA may not ultimately approve the BLA for deramiocel.
• The advisory committee meeting could raise concerns about deramiocel's efficacy or safety.
• The Phase 1 clinical trial of the StealthX vaccine may not be successful.
• The company's financial performance may be affected by unforeseen expenses or delays.
• The company's expectation of funding into 2027 excludes potential milestone payments and strategic use of capital.

Future Outlook

Capricor believes its available cash, cash equivalents, and marketable securities will be sufficient to cover anticipated expenses and capital requirements into 2027, excluding potential milestone payments and strategic use of capital.

Management Comments

• We continue to make strong progress in 2025 as we advance toward our goal of delivering the first approved therapy for Duchenne cardiomyopathya condition with no approved treatments, said Linda Marbn, Ph.D., Capricors Chief Executive Officer.
• We continue to have active dialogue with the FDA as they review our BLA and we remain on track with our PDUFA target action date of August 31, 2025.
• Preparations are progressing for our upcoming FDA advisory committee meeting, pre-approval inspection, and potential commercial launch.
• Financially, we ended the first quarter with a strong cash position of approximately $145 million, enabling us to continue executing strategically as we approach key value-driving milestones.

Industry Context

Capricor is focused on developing treatments for rare diseases, specifically Duchenne muscular dystrophy, where there is a significant unmet need. The company's progress with deramiocel and its StealthX platform positions it as a key player in the cell and exosome-based therapeutics space.

Comparison to Industry Standards

• Capricor's deramiocel is competing with other therapies in development for DMD, including gene therapies from companies like Sarepta Therapeutics and solid biosciences.
• The company's focus on cardiac function in DMD differentiates it from some competitors who are primarily targeting skeletal muscle function.
• The cash runway into 2027 provides Capricor with a competitive advantage compared to smaller biotech companies that may need to raise capital more frequently.
• The collaboration with NIAID on the StealthX vaccine platform aligns with industry trends towards developing innovative vaccines for future pandemics.

Management Changes

Stakeholder Impact

• Shareholders: The progress with deramiocel and the strong cash position are positive for shareholders.
• Patients with DMD: The potential approval of deramiocel could provide a new treatment option for DMD patients.
• Employees: The company's continued progress and financial stability are positive for employees.
• Commercial partners: The company is working with Nippon Shinyaku for the commercialization and distribution of deramiocel for DMD in the United States and Japan.

Next Steps

• Continue active dialogue with the FDA regarding the BLA for deramiocel.
• Prepare for the upcoming FDA advisory committee meeting and pre-approval inspection.
• Potentially launch deramiocel commercially, pending FDA approval.
• Support NIAID in the initiation of the Phase 1 clinical trial of the StealthX exosome vaccine.
• Participate in upcoming investor conferences and industry events.

Key Dates

Keywords

Capricor Therapeutics, Deramiocel, Duchenne Muscular Dystrophy, DMD, Biologics License Application, BLA, FDA, StealthX, Exosome, Vaccine, NIAID, Financial Results